Eagle Pharmaceuticals Inc
EGRX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.5M
Close$
$12.59
1225% upside
Current Fair Value
1225% upsideUndervalued by 1225% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $12.50 Million |
|---|---|
| Enterprise Value | $127.37 Million |
| Earnings per Share | $2.76 |
| Beta | 0.66 |
| Outstanding Shares | 13,090,852 |
Return
| Return on Equity | 4.74% |
|---|---|
| Return on Assets | 2.95% |
| Return on Invested Capital | 9.52% |
Valuation & Multiples
| P/E Ratio | 0.34 |
|---|---|
| PEG | -0.22 |
| Price to Sales | 0.05 |
| Price to Book Ratio | 0.05 |
| Enterprise Value to Revenue | 0.49 |
| Enterprise Value to EBIT | 4.21 |
| Enterprise Value to Net Income | 10 |
| Total Debt to Enterprise | 1.02 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$0.73
Consensus analyst estimateRevenue Estimate
$45.03 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.09%0% |
|---|---|
| Total Invested | $8,275▲ 96.46% |
| Investors Holding | 20% |
About Eagle Pharmaceuticals Inc
CEO: Scott Tarriff
